In silico models of acute inflammation in animals

Shock

Volumn 26, Issue 3, 2006, Pages 235-244

  Vodovotz, Yoram ^a,f   Chow, Carson C ^b,c,f   Bartels, John ^d   Lagoa, Claudio ^a   Prince, Jose M ^a   Levy, Ryan M ^a   Kumar, Rukmini ^b   Day, Judy ^b   Rubin, Jonathan ^b   Constantine, Greg ^b   Billiar, Timothy R ^a,f   Fink, Mitchell P ^a,e,f   Clermont, Gilles ^e,f  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d IMMUNETRICS INC   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f Ummunetrics Inc   (United States)

Author keywords

Inflammation; Mathematical model; Mouse; Rat; Sepsis; Trauma

Indexed keywords

LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BACTERIAL INFECTION; CONTROLLED STUDY; CYTOKINE RELEASE; DATA ANALYSIS; EXPERIMENTAL MODEL; FEMUR FRACTURE; FIBRIN CLOT; HEMORRHAGIC SHOCK; HIGH RISK PATIENT; INFLAMMATION; MATHEMATICAL MODEL; NONHUMAN; REVIEW; SEPSIS; SIMULATION;

ANIMALS; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; RATS;

EID: 33747341838     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000225413.13866.fo     Document Type: Review

References (101)

1. Marshall JC: Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 29:S99-S106, 2001.
2. Jarrar D, Chaudry IH, Wang P: Organ dysfunction following hemorrhage and sepsis: mechanisms and therapeutic approaches. Int J Mol Med 4:575-583, 1999. [review].
3. Schlag G, Redl H: Mediators of injury and inflammation. World J Surg 20:406-410, 1996.
4. Stoiser B, Knapp S, Thalhammer F, Locker GJ, Kofler J, Hollenstein U, Staudinger T, Wilfing A, Frass M, Burgmann H: Time course of immunological markers in patients with the systemic inflammatory response syndrome: evaluation of sCD14, sVCAM-1, sELAM-1, MIP-1 alpha and TGF-beta 2. Eur J Clin Invest 28:672-678, 1998.
5. Nathan C: Points of control in inflammation. Nature 420:846-852, 2002.
6. Marshall JC, Deitch E, Moldawer LL, Opal S, Redl H, Poll TV: Preclinical models of shock and sepsis: what can they tell us? Shock 24(suppl 1):1-6, 2005.
7. Levi M, van der Poll T, ten Cate H, van Deventer SJ: The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 27:3-9, 1997. [review].
8. Bone RC, Grodzin CJ, Balk RA: Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112:235-243, 1997.
9. Bone RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24:163-172, 1996.
10. Moore EE, Moore FA, Franciose RJ, Kim FJ, Biffl WL, Banerjee A: The postischemic gut serves as a priming bed for circulating neutrophils that provoke multiple organ failure. J Trauma 37:881-887, 1994. [review].
11. Moore FA, Moore EE, Sauaia A: Postinjury multiple-organ failure. In Mattox KL, Feliciano DV, Moore EE (eds.): Trauma. New York, NY: McGraw-Hill, pp 1427-1459, 1999.
12. Bone RC: Why sepsis trials fail. JAMA 276:565-566, 1996.
13. Food and Drug Administration. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. 2004;1.
14. Parker SJ, Watkins PE: Experimental models of gram-negative sepsis. Br J Surg 88:22-30, 2001.
15. Nemzek JA, Xiao HY, Minard AE, Bolgos GL, Remick DG: Humane endpoints in shock research. Shock 21:17-25, 2004.
16. Kitano H: Systems biology: a brief overview. Science 295:1662-1664, 2002.
17. Buchman TG, Cobb JP, Lapedes AS, Kepler TB: Complex systems analysis: a tool for shock research. Shock 16:248-251, 2001.
18. Neugebauer EA, Willy C, Sauerland S: Complexity and non-linearity in shock research: reductionism or synthesis? Shock 16:252-258, 2001.
19. Vodovotz Y, Clermont G, Chow C, An G: Mathematical models of the acute inflammatory response. Curr Opin Crit Care 10:383-390, 2004.
20. Alt W, Lauffenburger DA: Transient behavior of a chemotaxis system modelling certain types of tissue inflammation. J Math Biol 24:691-722, 1987.
21. An G: Agent-based computer simulation SIRS: building a bridge between basic science and clinical trials. Shock 16:266-273, 2001.
22. An G: In-silico experiments of existing and hypothetical cytokine-directed clinical trials using agent based modeling. Crit Care Med 32:2050-2060, 2004.
23. Ben David I, Price SE, Bortz DM, Greineder CF, Cohen SE, Bauer AL, Jackson TL, Younger JG: Dynamics of intrapulmonary bacterial growth in a murine model of repeated microaspiration. Am J Respir Cell Mol Biol 33:476-482, 2005.
24. Chow CC, Clermont G, Kumar R, Lagoa C, Tawadrous Z, Gallo D, Betten B, Bartels J, Constantine G, Fink MP, et al: The acute inflammatory response in diverse shock states. Shock 24:74-84, 2005.
25. Clermont G, Bartels J, Kumar R, Constantine G, Vodovotz Y, Chow C: In silico design of clinical trials: a method coming of age. Crit Care Med 32:2061-2070, 2004.
26. Chang S, Busche F, Vodovotz Y, Clermont G, Fink M: Integrating environmental factors into a mathematical model to predict mortality of septic patients. Shock 23(suppl 3):3, 2005. [abstract].
27. Levy R, Prince J, Clermont G, Kane J, Hierholzer C, Lagoa C, Fink M, Billiar T, Vodovotz Y: In silico models predict and in vivo studies verify that gut-derived LPS plays a minor role in activating the innate immune response after hemorrhage. Shock 23(suppl 3):6, 2005. [abstract].
28. Neugebauer EA, Willy C, Sauerland S: Complexity and non-linearity in shock research: reductionism or synthesis? Shock 16:252-258, 2001.
29. Tjardes T, Neugebauer E: Sepsis research in the next millennium: concentrate on the software rather than the hardware. Shock 17:1-8, 2002.
30. Kumar R, Clermont G, Vodovotz Y, Chow CC: The dynamics of acute inflammation. J Theor Biol 230:145-155, 2004.
31. Bellingan G: Inflammatory cell activation in sepsis. Br Med Bull 55:12-29, 1999.
32. Freeman BD, Natanson C: Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 9:1651-1663, 2000.
33. Volk HD, Reinke P, Docke WD: Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem Immunol 74:162-177, 2000.
34. Bone RC: Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 125:680-687, 1996.
35. Pinsky MR: Sepsis: a pro- and anti-inflammatory disequilibrium syndrome. Contrib Nephrol 132:354-366, 2001.
36. Nathan CF, Hibbs JB Jr: Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 3:65-70, 1991.
37. Johnson ML, Billiar TR: Roles of nitric oxide in surgical infection and sepsis. World J Surg 22:187-196, 1998.
38. Babior BM: Phagocytes and oxidative stress. Am J Med 109:33-44, 2000.
39. Matzinger P: The danger model: a renewed sense of self. Science 296:301-305, 2002.
40. Jaeschke H, Smith CW: Mechanisms of neutrophil-induced parenchymal cell injury. J Leukoc Biol 61:647-653, 1997.
41. Harbrecht BG, Billiar TR, Stadler J, Demetris AJ, Ochoa JB, Curran RD, Simmons RL: Nitric oxide synthesis serves to reduce hepatic damage during acute murine endotoxemia. Crit Care Med 20:1568-1574, 1992.
42. Florquin S, Amraoui Z, Dubois C, Decuyper J, Goldman M: The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice. J Exp Med 180:1153-1158, 1994.
43. Park JH, Chang SH, Lee KM, Shin SH: Protective effect of nitric oxide in an endotoxin-induced septic shock. Am J Surg 171:340-345, 1996.
44. Hack CE, Zeerleder S: The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 29:S21-S27, 2001.
45. Beutler B: Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity. Curr Opin Microbiol 3:23-28, 2000.
46. Ruiter DJ, van der Meulen J, Brouwer A, Hummel MJ, Mauw BJ, van der Ploeg JC, Wisse E: Uptake by liver cells of endotoxin following its intravenous injection. Lab Invest 45:38-45, 1981.
47. Maitra SK, Rachmilewitz D, Eberle D, Kaplowitz N: The hepatocellular uptake and biliary excretion of endotoxin in the rat. Hepatology 1:401-407, 1981.
48. Djeu JY, Serbousek D, Blanchard DK: Release of tumor necrosis factor by human polymorphonuclear leukocytes. Blood 76:1405-1409, 1990.
49. Romani L, Mencacci A, Cenci E, Spaccapelo R, Del Sero G, Nicoletti I, Trinchieri G, Bistoni F, Puccetti P: Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol 158:5349-5356, 1997.
50. Koller M, Clasbrummel B, Kollig E, Hahn MP, Muhr G: Major injury induces increased production of interleukin-10 in human granulocyte fractions. Langenbecks Arch Surg 383:460-465, 1998.
51. Glowacka E, Banasik M, Lewkowicz P, Tchorzewski H: The effect of LPS on neutrophils from patients with high risk of type 1 diabetes mellitus in relation to IL-8, IL-10 and IL-12 production and apoptosis in vitro. Scand J Immunol 55:210-217, 2002.
52. Cavaillon JM: Cytokines and macrophages. Biomed Pharmacother 48:445-453, 1994.
53. Bogdan C: Nitric oxide and the immune response. Nat Immunol 2:907-916, 2001.
54. Rees DD, Cunha FQ, Assreuy J, Herman AG, Moncada S: Sequential induction of nitric oxide synthase by Corynebacterium parvum in different organs of the mouse. Br J Pharmacol 114:689-693, 1995.
55. Santak B, Radermacher P, Iber T, Adler J, Wachter U, Vassilev D, Georgieff M, Vogt J: In vivo quantification of endotoxin-induced nitric oxide production in pigs from Na15NO3-infusion. Br J Pharmacol 122:1605-1610, 1997.
56. Bogdan C, Vodovotz Y, Nathan CF: Macrophage deactivation by interleukin 10. J Exp Med 174:1549-1555, 1991.
57. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, De Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209-1220, 1991.
58. Aderka D, Le JM, Vilcek J: IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 143:3517-3523, 1989.
59. Opal SM, DePalo VA: Anti-inflammatory cytokines. Chest 117:1162-1172, 2000.
60. Villiger PM, Kusari AB, Ten Dijke P, Lotz M: IL-1 beta and IL-6 selectively induce transforming growth factor-beta isoforms in human articular chondrocytes. J Immunol 151:3337-3344, 1993.
61. Chong H, Vodovotz Y, Cox GW, Barcellos-Hoff MH: Immunocytochemical detection of latent TGF-β activation in cultured macrophages. J Cell Physiol 178:275-283, 1999.
62. Maeda H, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S, Shiraishi A: TGF-β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J Immunol 155:4926-4932, 1995.
63. Peitzman AB, Billiar TR, Harbrecht BG, Kelly E, Udekwu AO, Simmons RL: Hemorrhagic shock. Curr Probl Surg 32:925-1002, 1995.
64. Hierholzer C, Billiar TR: Molecular mechanisms in the early phase of hemorrhagic shock. Langenbecks Arch Surg 386:302-308, 2001.
65. Le Tulzo Y, Shenkar R, Kaneko D, Moine P, Fantuzzi G, Dinarello CA, Abraham E: Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-kappaB regulation and cytokine expression. J Clin Invest 99:1516-1524, 1997.
66. Tracey KJ: The inflammatory reflex. Nature 420:853-859, 2002.
67. Roberts AB, Sporn MB: Transforming growth factor-β. , In Clark RAF (ed.): The Molecular and Cellular Biology of Wound Repair. New York, NY: Plenum Press, pp 275-308, 1996.
68. Reibman J, Meixler S, Lee TC, Gold LI, Cronstein BN, Haines KA, Kolasinski SL, Weissmann G: Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. Proc Natl Acad Sci U S A 88:6805-6809, 1991.
69. Brandes ME, Mai UEH, Ohura K, Wahl SM: Type I transforming growth factor-β receptors on neutrophils mediate chemotaxis to transforming growth factor-β. J Immunol 147:1600-1606, 1991.
70. Drake WT, Issekutz AC: Transforming growth factor-β1 enhances polymorphonuclear leucocyte accumulation in dermal inflammation and transendothelial migration by a priming action. Immunology 78:197-204, 1993.
71. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ: HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164:1768-1773, 2001.
72. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, et al: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201:1135-1143, 2005.
73. Maeda H, Shiraishi A: TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 156:73-78, 1996.
74. Parker JL, Adams HR: Selective inhibition of endothelium-dependent vasodilator capacity by Escherichia coli endotoxemia. Circ Res 72:539-551, 1993.
75. Graier WF, Myers PR, Rubin LJ, Adams HR, Parker JL: Escherichia coli endotoxin inhibits agonist-mediated cytosolic Ca2+ mobilization and nitric oxide biosynthesis in cultured endothelial cells. Circ Res 75:659-668, 1994.
76. Myers PR, Parker JL, Tanner MA, Adams HR: Effects of cytokines tumor necrosis factor alpha and interleukin 1 beta on endotoxin-mediated inhibition of endothelium-derived relaxing factor bioactivity and nitric oxide production in vascular endothelium. Shock 1:73-78, 1994.
77. Parker JL, Myers PR, Zhong Q, Kim K, Adams HR: Inhibition of endothelium-dependent vasodilation by Escherichia coli endotoxemia. Shock 2:451-458, 1994.
78. Szabo C: Alterations in nitric oxide production in various forms of circulatory shock. New Horiz 3:2-32, 1995.
79. Ochoa JB, Udekwu AO, Billiar TR, Curran RD, Cerra FB, Simmons RL, Peitzman AB: Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 214:621-626, 1991.
80. Jacob TD, Ochoa JB, Udekwu AO, Wilkinson J, Murray T, Billiar TR, Simmons RL, Marion DW, Peitzman AB: Nitric oxide production is inhibited in trauma patients. J Trauma 35:590-596, 1993.
81. Bernard AC, Mistry SK, Morris SM Jr, O'Brien WE, Tsuei BJ, Maley ME, Shirley LA, Kearney PA, Boulanger BR, Ochoa JB: Alterations in arginine metabolic enzymes in trauma. Shock 15:215-219, 2001.
82. Lagoa C, Vodovotz Y, Billiar TR: Exploring the host's response to trauma and hemorrhagic shock using a combination of mathematical simulations and genomics. Shock 23(suppl 3):67, 2005. [abstract].
83. Herman CM, Kraft AR, Smith KR, Artnak J, Chisholm FC, Dickson LG, Homer LD: Endogenous endotoxemia during hemorrhagic shock in the subhuman primate. Surg Forum 23:14-15, 1972.
84. Woodruff PW, O'Carroll DI, Koizumi S, Fine J: Role of the intestinal flora in major trauma. J Infect Dis 128(suppl):290-294, 1973.
85. Herman CM, Kraft AR, Smith KR, Artnak EJ, Chisholm FC, Dickson LG, McKee AE Jr, Homer LD, Levin J: The relationship of circulating endogenous endotoxin to hemorrhagic shock in the baboon. Ann Surg 179:910-916, 1974.
86. Rhodes RS, DePalma RG, Robinson AV: Relationship of critical uptake volume to energy production and endotoxemia in late hemorrhagic shock. Am J Surg 130:560-564, 1975.
87. Gaffin SL, Grinberg Z, Abraham C, Birkhan J, Shechter Y: Protection against hemorrhagic shock in the cat by human plasma containing endotoxin-specific antibodies. J Surg Res 31:18-21, 1981.
88. Pohlson EC, Suehiro A, Ziegler EJ, Suehiro G, McNamara JJ: Antiserum to endotoxin in hemorrhagic shock. J Surg Res 45:467-471, 1988.
89. Rush BF Jr, Sori AJ, Murphy TF, Smith S, Flanagan JJ Jr, Machiedo GW: Endotoxemia and bacteremia during hemorrhagic shock. The link between trauma and sepsis? Ann Surg 207:549-554, 1988.
90. Bahrami S, Schlag G, Yao YM, Redl H: Significance of translocation/ endotoxin in the development of systemic sepsis following trauma and/or haemorrhage. Prog Clin Biol Res 392:197-208, 1995.
91. Guo W, Ding J, Huang Q, Jerrells T, Deitch EA: Alterations in intestinal bacterial flora modulate the systemic cytokine response to hemorrhagic shock. Am J Physiol 269:G827-G832, 1995.
92. Jiang J, Bahrami S, Leichtfried G, Redl H, Ohlinger W, Schlag G: Kinetics of endotoxin and tumor necrosis factor appearance in portal and systemic circulation after hemorrhagic shock in rats. Ann Surg 221:100-106, 1995.
93. Shimizu T, Tani T, Hanasawa K, Endo Y, Kodama M: The role of bacterial translocation on neutrophil activation during hemorrhagic shock in rats. Shock 16:59-63, 2001.
94. Ayala A, Perrin MM, Meldrum DR, Ertel W, Chaudry IH: Hemorrhage induces an increase in serum TNF which is not associated with elevated levels of endotoxin. Cytokine 2:170-174, 1990.
95. Peitzman AB, Udekwu AO, Ochoa J, Smith S: Bacterial translocation in trauma patients. J Trauma 31:1083-1086, 1991.
96. Roumen RM, Hendriks T, Wevers RA, Goris JA: Intestinal permeability after severe trauma and hemorrhagic shock is increased without relation to septic complications. Arch Surg 128:453-457, 1993.
97. Endo S, Inada K, Yamada Y, Takakuwa T, Kasai T, Nakae H, Yoshida M, Ceska M: Plasma endotoxin and cytokine concentrations in patients with hemorrhagic shock. Crit Care Med 22:949-955, 1994.
98. Beutler B: Innate immune sensing of microbial infection: the mechanism and the therapeutic challenge. Wien Med Wochenschr 152:547-551, 2002.
99. Haziot A, Ferrero E, Lin XY, Stewart CL, Goyert SM: CD14-deficient mice are exquisitely insensitive to the effects of LPS. Prog Clin Biol Res 392:349-351, 1995.
100. Gneiting T, Raftery AE: Atmospheric science: weather forecasting with ensemble methods. Science 310:248-249, 2005.
101. Ahrenholz DH, Simmons RL: Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surgery 88:41-47, 1980.